Company: Novartis Institutes for BioMedical Research
Job title: Investigator III
Huaixiang is a research investigator at Novartis Institutes for BioMedical Research (NIBR) in Cambridge MA conducting oncology translational research on patient selection, drug combination, resistance mechanism, and clinical biomarkers for small molecule inhibitors of SHP2, MAPK, MET, PIM, mTOR, WNT, etc. He earned his bachelor’s degree in Biological Science from Xiamen University in China and his Ph.D. degree in Biochemistry from University of Utah under the guidance of Dr. Jared Rutter studying nutrient sensing kinases and mitochondria biology. His completed his postdoctoral training in the field of Wnt signalling with Dr. Feng Cong, also at NIBR. He has > 19 publications including first author papers in Science and Nature, and >6 patents. He is also a mentor of the NIBR post-doctoral fellow program. He has been working on the first-in-class allosteric SHP2 phosphatase inhibitor made by Novartis for more than six years.
Targeting Upstream Activation of Mutant KRAS via Allosteric Inhibition of SHP2 Phosphatase 2:15 pm
The newly appreciated role of RTK and SHP2 for mutant KRAS activation The RTK/SHP2 mediated MAPK pathway feedback activation upon ERK inhibition Potential mechanisms of resistance to SHP2 inhibitorsRead more
day: Day One